Pharvaris (NASDAQ:PHVS) Upgraded to Hold at Wall Street Zen

Pharvaris (NASDAQ:PHVS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other analysts also recently issued reports about the company. Leerink Partners set a $38.00 target price on Pharvaris in a research report on Wednesday, December 3rd. Royal Bank Of Canada initiated coverage on Pharvaris in a research report on Monday, March 9th. They set an “outperform” rating and a $52.00 price target on the stock. Guggenheim increased their price target on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Oppenheimer lifted their price objective on Pharvaris from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Finally, Bank of America boosted their price objective on Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Thursday, December 4th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and an average price target of $41.70.

Pharvaris Stock Down 0.1%

Pharvaris stock opened at $27.35 on Friday. The firm has a 50 day moving average price of $26.91 and a 200-day moving average price of $25.24. Pharvaris has a twelve month low of $11.51 and a twelve month high of $29.80. The company has a market capitalization of $1.49 billion, a P/E ratio of -8.52 and a beta of -2.78.

Hedge Funds Weigh In On Pharvaris

Hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Pharvaris during the 4th quarter valued at $35,000. JPMorgan Chase & Co. boosted its stake in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Pharvaris in the 3rd quarter worth about $75,000. Barclays PLC purchased a new position in Pharvaris during the 4th quarter valued at about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Pharvaris during the 4th quarter valued at about $86,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.